tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Cambium Bio Secures A$2.12 Million for Phase 3 Trials

Story Highlights
Cambium Bio Secures A$2.12 Million for Phase 3 Trials

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Regeneus Ltd. ( (AU:CMB) ) just unveiled an announcement.

Cambium Bio Limited has successfully raised A$2.12 million through a fully-subscribed placement of new shares, with significant investment from Da Jyun Capital Investment Corporation, a Taiwanese firm experienced in regenerative medicine. This funding will support the initiation of Phase 3 trials for Elate Ocular and enhance Cambium Bio’s strategic positioning in the market, potentially leading to global licensing discussions with major pharmaceutical companies.

More about Regeneus Ltd.

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on ophthalmology and tissue repair.

Average Trading Volume: 10,479

Technical Sentiment Signal: Sell

Current Market Cap: A$5.85M

For a thorough assessment of CMB stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1